Bal Pharma Limited (NSE: BALPHARMA)

Market Cap	1.96B
Revenue (ttm)	3.24B
Net Income (ttm)	76.63M
Shares Out	n/a
EPS (ttm)	4.74
PE Ratio	25.51
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Sep 17, 2024

Volume	5,426
Open	120.00
Previous Close	119.95
Day's Range	120.00 - 122.34
52-Week Range	88.95 - 157.98
Beta	0.52
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 14, 2025

About Bal Pharma

Bal Pharma Limited, together with its subsidiaries, manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company offers prescription drugs, generics, OTC products, intravenous infusion products, and bulk drugs. It also provides anti-infectives, pain management, respiratory care, and women's health products under the Aziwin, Ebay, Balvibe, MNF, Ocium, and Monogesic Plus Gel brands; diabetic care products under the Diabend and Diabend M Group brands; herbal/ayurvedic p...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1987
• Employees: 868
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: BALPHARMA

Financial Performance

In 2023, Bal Pharma's revenue was 3.39 billion, an increase of 11.51% compared to the previous year's 3.04 billion. Earnings were 73.92 million, an increase of 187.44%.